Background

Mitochondria, the energy producers within cells, are key organelles for sustaining life. In aging research, mitochondria have long been treated as simple causative agents that damage cells by producing reactive oxygen species. However, the molecular-level mechanisms explaining how the fine molecular arrangements of oxidative phosphorylation (OXPHOS) complexes, responsible for cellular respiration, or complexes regulating cell death, directly induce aging, have not been fully elucidated. Existing studies were limited to observing the quantitative decrease of individual proteins or genetic mutations. They failed to comprehensively present the specific pathways through which changes in binding ratios between complexes or conformational changes lead to systemic decline.

Supramolecular complexes in the outer and inner mitochondrial membranes interact with highly precise stoichiometry. The assembly state of electron transport chain (ETC) complexes, the regulation of the opening and closing of the mitochondrial permeability transition pore (mPTP), and protein quality control systems maintain cellular metabolic homeostasis. As individuals age, the structural integrity of these complexes may be compromised, or abnormal post-translational modifications (PTMs) may occur. Consequently, a vicious cycle arises in which the collapse of biomolecular complexes is amplified beyond cellular aging into inflammaging, a chronic systemic inflammation. The academic community has called for precision therapeutic approaches that directly correct the structure of damaged complexes or block abnormal gating, moving beyond simple antioxidant administration.

Key Findings

Researchers integrated cryo-electron microscopy (cryo-EM) structural analysis data to identify the molecular pathways through which structural damage to mitochondrial macromolecular complexes leads to cellular aging and chronic diseases. They confirmed that assembly defects in ETC supercomplexes and abnormalities in the interaction between mitochondrial DNA (mtDNA) and proteins are the starting points for decreased energy production. When the ratio between complex monomers is disrupted or molecular conformations change, the mPTP opens abnormally, leading to the loss of membrane potential. PTM abnormalities, such as the failure of deacetylation regulation by SIRT3, were identified as key mechanisms that destabilize complex structures and promote systemic metabolic dysfunction.

These molecular-level damages manifest in different patterns depending on the tissue. In skin aging models, deficiencies in Electron Transport Chain Complex I were prominent. In ovarian aging models, it was revealed that an imbalance in Bcl-2 family proteins directly leads to the failure of cell death regulation. The researchers newly categorized nine age-related diseases, including neurodegenerative diseases like Alzheimer's, cardiovascular diseases, and cancer, according to their dependence on mitochondrial complexes. For example, in the pathogenesis of Alzheimer's disease, dysfunction of the TIM/TOM complex, a protein transport machinery spanning the inner and outer mitochondrial membranes, plays a decisive role. Certain cancer cells exhibiting anticancer drug resistance were found to rely heavily on a modified metabolic circuit of the ATP synthase complex.

Specific treatment approaches to address structural vulnerabilities were also identified. Representative examples include small-molecule stabilizers that support the assembly of ETC supercomplexes, peptide-based inhibitors of mPTP opening, and techniques to restore mtDNA-protein binding mismatches using CRISPR gene-editing technology. Inhibitory peptides designed based on binding site data identified via cryo-EM effectively blocked membrane potential collapse and inflammatory responses by selectively inhibiting the abnormal opening of the mitochondrial permeability transition pore.

Significance and Outlook

This research redefines mitochondria-related diseases not merely as a decline in energy metabolism, but from the perspective of the structural instability of supramolecular complexes. By linking high-resolution structural information based on cryo-EM with drug discovery strategies, it has established a research framework where structural biological discoveries lead directly to the development of targeted therapeutics. The theoretical basis for a personalized therapeutic strategy that identifies and targets tissue-specific vulnerable complexes, rather than aging itself as a single target, has been established.

Technical barriers remain to be overcome for the practical application of new drug development. Technology to deliver drugs precisely through the mitochondrial double membrane to reach the matrix or inner membrane complexes is still limited. Subsequent non-clinical validation is required to precisely define a therapeutic window, ensuring that small-molecule compounds stabilizing inter-complex interactions do not inhibit the physiological energy metabolism of normal cells. It is also necessary to systematically verify the potential impact on the overall mitochondrial quality control mechanism during long-term administration.